-
1
-
-
33846572874
-
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
-
Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-386.
-
(2007)
Neurology
, vol.68
, Issue.5
, pp. 384-386
-
-
Dorsey, E.R.1
Constantinescu, R.2
Thompson, J.P.3
-
2
-
-
77953425159
-
Mitochondrial therapies for Parkinson’s disease
-
Thomas B, Beal MF.Mitochondrial therapies for Parkinson’s disease. Mov Disord. 2010;25(suppl 1):S155-S160.
-
(2010)
Mov Disord
, vol.25
, pp. S155-S160
-
-
Thomas, B.1
Beal, M.F.2
-
3
-
-
71849091967
-
Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease
-
Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(suppl 3):S189-S194.
-
(2009)
Parkinsonism Relat Disord
, vol.15
, pp. S189-S194
-
-
Beal, M.F.1
-
4
-
-
77949565639
-
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I
-
Burchell VS, Gandhi S, Deas E, Wood NW, Abramov AY, Plun-Favreau H. Targeting mitochondrial dysfunction in neurodegenerative disease: part I. Expert Opin Ther Targets. 2010;14(4):369-385.
-
(2010)
Expert Opin Ther Targets
, vol.14
, Issue.4
, pp. 369-385
-
-
Burchell, V.S.1
Gandhi, S.2
Deas, E.3
Wood, N.W.4
Abramov, A.Y.5
Plun-Favreau, H.6
-
5
-
-
20444365828
-
Therapeutic role of coenzyme Q(10) in Parkinson’s disease
-
Shults CW. Therapeutic role of coenzyme Q(10) in Parkinson’s disease. Pharmacol Ther. 2005;107(1):120-130.
-
(2005)
Pharmacol Ther
, vol.107
, Issue.1
, pp. 120-130
-
-
Shults, C.W.1
-
6
-
-
0030612117
-
Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects
-
Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997;42(2):261-264.
-
(1997)
Ann Neurol
, vol.42
, Issue.2
, pp. 261-264
-
-
Shults, C.W.1
Haas, R.H.2
Passov, D.3
Beal, M.F.4
-
8
-
-
0031044805
-
Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10
-
Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington’s disease and effects of coenzyme Q10. Ann Neurol. 1997;41(2):160-165.
-
(1997)
Ann Neurol
, vol.41
, Issue.2
, pp. 160-165
-
-
Koroshetz, W.J.1
Jenkins, B.G.2
Rosen, B.R.3
Beal, M.F.4
-
9
-
-
56049088295
-
Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: Predictor of efficacy of vitamin E and coenzyme Q10 therapy
-
Cooper JM, Korlipara LV, Hart PE, Bradley JL, Schapira AH. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15(12):1371-1379.
-
(2008)
Eur J Neurol
, vol.15
, Issue.12
, pp. 1371-1379
-
-
Cooper, J.M.1
Korlipara, L.V.2
Hart, P.E.3
Bradley, J.L.4
Schapira, A.H.5
-
10
-
-
49249087500
-
Short-term effects of coenzyme Q10 in progressive supranuclear palsy: A randomized, placebo-controlled trial
-
Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23(7):942-949.
-
(2008)
Mov Disord
, vol.23
, Issue.7
, pp. 942-949
-
-
Stamelou, M.1
Reuss, A.2
Pilatus, U.3
-
11
-
-
0036771852
-
Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline
-
Shults CW, Oakes D, Kieburtz K, et al; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550.
-
(2002)
Arch Neurol
, vol.59
, Issue.10
, pp. 1541-1550
-
-
Shults, C.W.1
Oakes, D.2
Kieburtz, K.3
-
12
-
-
34447252358
-
German Coenzyme Q(10) Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease
-
Storch A, Jost WH, Vieregge P, et al; German Coenzyme Q(10) Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64(7): 938-944.
-
(2007)
Arch Neurol
, vol.64
, Issue.7
, pp. 938-944
-
-
Storch, A.1
Jost, W.H.2
Vieregge, P.3
-
13
-
-
0000224448
-
Members of the UPDRS Development Committee
-
In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds, Florham Park, NJ: Macmillan Healthcare Information
-
Fahn S, Elton R; Members of the UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Vol 2. Florham Park, NJ: Macmillan Healthcare Information;1987:153-163.
-
(1987)
Recent Developments in Parkinson’s Disease
, vol.2
, pp. 153-163
-
-
Fahn, S.1
Elton, R.2
-
14
-
-
0016823810
-
Mini-mental state: A practical method for grading the cognitive state of patients for the clinician
-
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
-
(1975)
J Psychiatr Res
, vol.12
, Issue.3
, pp. 189-198
-
-
Folstein, M.F.1
Folstein, S.E.2
McHugh, P.R.3
-
15
-
-
35148882113
-
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
-
Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69(15):1480-1490.
-
(2007)
Neurology
, vol.69
, Issue.15
, pp. 1480-1490
-
-
-
16
-
-
3042717908
-
Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease
-
Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol. 2004;188(2):491-494.
-
(2004)
Exp Neurol
, vol.188
, Issue.2
, pp. 491-494
-
-
Shults, C.W.1
Flint Beal, M.2
Song, D.3
Fontaine, D.4
-
17
-
-
33846115045
-
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease
-
NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20-28.
-
(2007)
Neurology
, vol.68
, Issue.1
, pp. 20-28
-
-
-
18
-
-
77955792985
-
Protect Study Group. A double-blind, placebo-controlled study to assess themitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease
-
Snow BJ, Rolfe FL, Lockhart MM, et al; Protect Study Group. A double-blind, placebo-controlled study to assess themitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord. 2010;25(11):1670-1674.
-
(2010)
Mov Disord
, vol.25
, Issue.11
, pp. 1670-1674
-
-
Snow, B.J.1
Rolfe, F.L.2
Lockhart, M.M.3
-
19
-
-
79959242100
-
Mitochondrial contribution to Parkinson’s disease pathogenesis
-
Schapira AH, Gegg M. Mitochondrial contribution to Parkinson’s disease pathogenesis. Parkinsons Dis. 2011;2011:159160.
-
(2011)
Parkinsons Dis
, vol.2011
, pp. 159160
-
-
Schapira, A.H.1
Gegg, M.2
-
20
-
-
55849122639
-
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis
-
Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600-609.
-
(2008)
Nat Clin Pract Neurol
, vol.4
, Issue.11
, pp. 600-609
-
-
Henchcliffe, C.1
Beal, M.F.2
-
21
-
-
77952673222
-
Coenzyme Q10 in human blood: Native levels and determinants of oxidation during processing and storage
-
Franke AA, Morrison CM, Bakke JL, Custer LJ, Li X, Cooney RV. Coenzyme Q10 in human blood: native levels and determinants of oxidation during processing and storage. Free Radic Biol Med. 2010;48(12):1610-1617.
-
(2010)
Free Radic Biol Med
, vol.48
, Issue.12
, pp. 1610-1617
-
-
Franke, A.A.1
Morrison, C.M.2
Bakke, J.L.3
Custer, L.J.4
Li, X.5
Cooney, R.V.6
-
22
-
-
34248162014
-
Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations
-
Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7(suppl): S78-S88.
-
(2007)
Mitochondrion
, vol.7
, pp. S78-S88
-
-
Bhagavan, H.N.1
Chopra, R.K.2
-
23
-
-
34248170185
-
Coenzyme Q10 and statins: Biochemical and clinical implications
-
Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion. 2007;7(suppl):S168-S174.
-
(2007)
Mitochondrion
, vol.7
, pp. S168-S174
-
-
Littarru, G.P.1
Langsjoen, P.2
-
24
-
-
23644449049
-
Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons
-
Wang XL, Rainwater DL, Mahaney MC, Stocker R. Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons. Am J Clin Nutr. 2004;80(3):649-655.
-
(2004)
Am J Clin Nutr
, vol.80
, Issue.3
, pp. 649-655
-
-
Wang, X.L.1
Rainwater, D.L.2
Mahaney, M.C.3
Stocker, R.4
-
25
-
-
13844298846
-
Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice
-
McDonald SR, Sohal RS, Forster MJ. Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice. Free Radic Biol Med. 2005;38(6):729-736.
-
(2005)
Free Radic Biol Med
, vol.38
, Issue.6
, pp. 729-736
-
-
McDonald, S.R.1
Sohal, R.S.2
Forster, M.J.3
-
26
-
-
84859856337
-
Motor signs in the prodromal phase of Parkinson’s disease
-
Maetzler W, Hausdorff JM. Motor signs in the prodromal phase of Parkinson’s disease. Mov Disord. 2012;27(5):627-633.
-
(2012)
Mov Disord
, vol.27
, Issue.5
, pp. 627-633
-
-
Maetzler, W.1
Hausdorff, J.M.2
-
27
-
-
73949157929
-
Parkinson Study Group DATATOP and PRECEPT investigators. A comparison of treatment thresholds in two large Parkinson’s disease clinical trial cohorts
-
Marras C, Lang AE, Eberly SW, et al; Parkinson Study Group DATATOP and PRECEPT investigators. A comparison of treatment thresholds in two large Parkinson’s disease clinical trial cohorts. Mov Disord. 2009;24(16):2370-2378.
-
(2009)
Mov Disord
, vol.24
, Issue.16
, pp. 2370-2378
-
-
Marras, C.1
Lang, A.E.2
Eberly, S.W.3
-
28
-
-
85009226418
-
A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease
-
Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57(3):397-404.
-
(2001)
Neurology
, vol.57
, Issue.3
, pp. 397-404
-
-
|